Velocity Principal Investigators Douglas K. Logan, MD, and David Ensz, MD, are authors of a newly published Nature Communications article, “Immunogenicity and safety of mRNA-based seasonal influenza vaccines encoding hemagglutinin and neuraminidase.”
The Phase 1/2 Moderna trial results “demonstrate the proof of concept that mRNA-1020 and mRNA-1030 elicit similar HA-specific immune responses to [hemagglutinin] HA-only vaccines, while also inducing [neuraminidase] NA-specific immune responses with no additional reactogenicity beyond an mRNA-based, HA-only-containing vaccine.” And the paper continues, “Improving NA content of seasonal influenza vaccines has been identified as a major focus to increase effectiveness.”
Read the article: https://www.nature.com/articles/s41467-025-60938-4
